Cystic Fibrosis

Cystic fibrosis (CF) is an autosomal recessive genetic disorder affecting the cystic fibrosis transmembrane conductance regulator (CFTR) protein, leading to abnormal ion transport and viscous secretions in multiple organ systems, primarily the lungs and pancreas. It is the most common life-threatening inherited disorder in Caucasian populations, with an incidence of approximately 1 in 2,500–3,500 live births and a prevalence of ~30,000 patients in the United States. CF affects multiple organ systems—pulmonary disease (chronic suppurative airway infection) and pancreatic insufficiency being most clinically significant—making it a complex multisystem disease requiring coordinated specialty care. The median survival has increased dramatically to >50 years with modern management, though CF remains a major cause of morbidity in pediatric and adult pulmonology. Understanding CF pathophysiology, diagnosis, and management is essential for USMLE preparation, particularly given the frequent board emphasis on genetic inheritance, pancreatic complications, and pulmonary exacerbations.

The fundamental defect in CF involves mutations in the CFTR gene (located on chromosome 7q31), which encodes a chloride channel protein critical for regulating salt and water balance across epithelial surfaces. Over 2,000 mutations have been identified; the most common is ΔF508 (deletion of phenylalanine at position 508), accounting for ~70% of CF chromosomes globally. The pathophysiology unfolds through several interconnected mechanisms:

- CFTR dysfunction and ion transport abnormality: The CFTR protein normally functions as a cAMP-regulated chloride channel in epithelial cell apical membranes. In CF, defective CFTR leads to impaired chloride secretion into the airway lumen and paradoxically increased sodium reabsorption via the epithelial sodium channel (ENaC). This creates a concentration gradient that drives water absorption from the airway lumen into epithelial cells, resulting in dehydrated, viscous secretions. The reduced chloride in airway fluid and impaired water secretion generate an osmotically unfavorable environment, depleting the airway surface liquid (ASL) layer. This causes collapse of the mucus clearance layer and abnormal mucociliary clearance, setting the stage for chronic bacterial colonization.

- Chronic airway infection and inflammatory cascade: The impaired mucociliary clearance allows pathogenic bacteria—particularly Pseudomonas aeruginosa (the most clinically significant organism), Staphylococcus aureus, Burkholderia cepacia, and *Haemophilus influenzae*—to colonize the airways chronically. This begins in childhood and progressively worsens. The thick, adherent biofilms formed by these organisms (especially Pseudomonas) are resistant to antibiotics and immune clearance. The chronic infection triggers an exaggerated, dysregulated inflammatory response characterized by massive recruitment of neutrophils, which release elastase, reactive oxygen species, and proteolytic enzymes that damage the airways. Unlike acute infection, this inflammation is disproportionate to bacterial burden and becomes self-perpetuating. Over decades, this leads to bronchiectasis (irreversible bronchial dilatation and destruction), bronchial wall thickening, mucus plugging, and progressive airway obstruction.

- Pancreatic insufficiency: The same CFTR dysfunction occurs in pancreatic ducts, where the channel normally secretes bicarbonate-rich fluid to neutralize gastric acid and hydrate pancreatic secretions. Without adequate chloride and water secretion, pancreatic duct fluid becomes thick and acidic, causing ductal obstruction. The acidic milieu inactivates pancreatic enzymes (lipase, amylase, protease) and impairs their normal function, while the obstruction triggers autodigestive inflammation and acinar cell destruction. This culminates in pancreatic exocrine insufficiency (present in ~85% of CF patients) with fat malabsorption (steatorrhea), fat-soluble vitamin deficiencies (A, D, E, K), and protein malabsorption. Progressive acinar destruction eventually leads to pancreatic endocrine insufficiency and CF-related diabetes (CFRD) in 20–50% of patients, driven by loss of β-cell mass and chronic inflammation.

- Additional organ involvement: CFTR dysfunction in the biliary system causes thick bile and biliary obstruction, leading to focal biliary cirrhosis in 5–10% of patients and, rarely, CF-related cirrhosis with portal hypertension. The intestine experiences meconium ileus in neonates (from inspissated meconium due to pancreatic insufficiency and abnormal secretions) and distal intestinal obstruction syndrome (DIOS) in older patients. Reproductive tract involvement results in congenital bilateral absence of the vas deferens (CBAVD) in >95% of CF males (obstructive azoospermia) and reduced fertility in females due to thick cervical mucus and malnutrition. CF-related bone disease results from vitamin D deficiency, chronic inflammation, and malabsorption.

- Cellular mechanisms: At the molecular level, defective CFTR protein undergoes misfolding and is targeted for proteasomal degradation (for ΔF508 and similar class II mutations) rather than trafficking to the apical membrane. Some mutations produce non-functional channels at the surface (class III-IV), while others produce no protein at all (class I, V, VI). This diversity in mutation types explains phenotypic heterogeneity in CF.

- CFTR gene mutations (primary cause): CF is caused exclusively by inherited mutations in the CFTR gene inherited in an autosomal recessive pattern, meaning an affected individual carries two mutant alleles (one from each parent, who are typically asymptomatic carriers). Over 2,000 distinct mutations have been documented. The most common classes include: (1) Class I mutations (nonsense, frameshift mutations)—produce no functional protein; (2) Class II mutations (ΔF508, other misfolding mutations)—produce truncated or misfold proteins degraded before reaching the cell surface; (3) Class III mutations (defective regulation, e.g., G551D)—produce protein that reaches the surface but has impaired channel function; (4) Class IV mutations (reduced conductance)—produce functional channels with reduced ion transport; (5) Class V mutations (reduced expression)—produce normal protein but in insufficient quantity; (6) Class VI mutations (accelerated degradation)—produce protein with shortened half-life at the apical membrane. Mutation class partially predicts phenotype: Class I-II mutations typically correlate with pancreatic insufficiency and more severe lung disease, while Class III-VI mutations (particularly G551D) may present with milder phenotypes and pancreatic sufficiency.

- Genetic modifiers and variable penetrance: Beyond CFTR genotype, disease severity is modified by genetic polymorphisms in genes encoding TNF-α, TGF-β, mannose-binding lectin, and other immune mediators, as well as modifier genes like SLC6A14. These explain why two patients with identical CFTR mutations can have dramatically different disease progression.

- No environmental "causes": CF is purely genetic; environmental factors do not cause CF but significantly influence disease progression (see complications section). There are no secondary or acquired forms of CF.

CF manifests across multiple organ systems, with pulmonary and pancreatic disease predominating. Presentation varies by age and genotype, ranging from neonatal screening-detected cases (now ~95% in developed countries) to late diagnosis in adolescents/adults with atypical presentations.

- Chronic productive cough: The hallmark respiratory symptom, typically beginning in infancy and persisting throughout life. The cough is initially dry but becomes productive, especially with respiratory infections. Sputum is thick, tenacious, and often green-tinged from Pseudomonas colonization. Patients may expectorate small plugs of thick mucus. The cough is often worst upon waking or during/after exertion, reflecting postural drainage and mobilization of airway secretions. Physiologically, the cough reflects both excessive mucus production and impaired mucociliary clearance, requiring heroic efforts to clear secretions.

- Recurrent/chronic respiratory infections: CF patients experience recurrent lower respiratory tract infections beginning in early childhood, with Staphylococcus aureus and Haemophilus influenzae predominating initially, then transition to Pseudomonas aeruginosa (often by age 5–10 years). Infections manifest as acute illness with fever, increased cough, purulent sputum, and decline in pulmonary function; some infections resolve partially but incompletely, leading to persistent colonization. Chronic Pseudomonas colonization is an almost universal feature of CF lung disease by adulthood. Exacerbations may be triggered by respiratory viral infections or spontaneously.

- Steatorrhea and malabsorption: Greasy, foul-smelling stools present from infancy in pancreatic-insufficient CF (present in ~85%). Patients fail to gain weight despite adequate oral intake, have poor linear growth, and manifest signs of fat-soluble vitamin deficiency: vitamin A deficiency causes nyctalopia (night blindness); vitamin D deficiency causes hypocalcemia, rickets, and bone disease; vitamin E deficiency predisposes to neurologic complications; vitamin K deficiency impairs coagulation. Some patients present with failure to thrive as the initial manifestation. Pancreatic-sufficient CF patients (15%) typically have normal stools and growth.

- Abdominal pain and pancreatic symptoms: Pancreatic inflammation may cause acute or chronic abdominal pain, particularly epigastric. Some CF patients develop recurrent acute pancreatitis (though less common than in hereditary pancreatitis). Chronic pancreatitis is evidenced by pancreatic ductal dilatation, atrophy, and fat infiltration on imaging. CF-related diabetes (CFRD) develops in 20–50% and typically presents in late childhood to early adulthood with polyuria, polydipsia, or incidental hyperglycemia on glucose tolerance testing; CFRD often requires insulin and carries worse prognosis than CF without diabetes.

- Nasal polyposis and sinusitis: Chronic rhinosinusitis affects 30–70% of CF patients and results from impaired mucociliary clearance in paranasal sinuses and nasal cavity. Nasal polyps occur in 15–48% and manifest as nasal obstruction, hyponasal speech, snoring, or sleep apnea. This is so common in CF that finding nasal polyps in a child with sinusitis should prompt CF testing.

- Meconium ileus (neonatal presentation): In 15–20% of CF newborns, meconium ileus presents as intestinal obstruction within the first days of life, manifesting with abdominal distention, bilious vomiting, and failure to pass meconium. The meconium is abnormally inspissated (thick, tenacious) due to pancreatic enzyme insufficiency and abnormal intestinal secretions. This is a classic neonatal CF presentation and indication for immediate sweat chloride testing.

- Distal intestinal obstruction syndrome (DIOS): CF patients (typically adolescents/adults) may develop DIOS characterized by acute or chronic partial intestinal obstruction from inspissated intraluminal material, typically at the ileocecal junction. Presents with crampy abdominal pain, nausea, vomiting, and abdominal distention. Risk factors include dehydration, pancreatic insufficiency, and reduced physical activity.

- Salty-tasting skin: Parents may note that kissing their CF child's skin tastes salty, reflecting elevated sweat electrolytes. Some describe salt crystals on the skin after perspiration.

- Atypical presentations: Some patients (pancreatic-sufficient CF, late-diagnosed cases, or milder mutations) present atypically with: isolated chronic pancreatitis, recurrent sinusitis with nasal polyps, male infertility (from CBAVD), meconium ileus equivalent (DIOS in older patients), or neonatal cholestasis. These delay diagnosis into adulthood; hence, CF should be considered in any adult with unexplained chronic pancreatitis, bronchiectasis, or CBAVD.

CF diagnosis requires demonstration of CFTR dysfunction through sweat testing combined with clinical findings or genetic mutation identification. Modern approaches integrate neonatal screening, clinical suspicion, and molecular/biochemical confirmation.

The test is highly sensitive and specific when properly performed by trained technicians (sensitivity ~99%, specificity >99%). False negatives are rare but may occur in pseudohypoaldosteronism, a different genetic disorder with similar presentation. Test validity requires adequate sweat collection (minimum 75 mg sweat); inadequate collection is common in infants and can be misinterpreted. Borderline values (40–59 mEq/L) require careful interpretation and often genetic testing or repeat sweat testing.

- Genetic testing: CFTR gene sequencing or targeted mutation panels identify CFTR mutations. Current guidelines recommend testing if: (1) sweat chloride is borderline (40–59 mEq/L), (2) clinical suspicion is high but sweat chloride is <40 mEq/L (rare CF variants), or (3) carrier screening in relatives. Testing identifies mutation class, which provides prognostic information. Neonatal screening programs often use immunoreactive trypsinogen (IRT) elevation as initial screening (from dried blood spots), followed by confirmatory sweat testing or genetic testing.

- Clinical criteria for diagnosis (CF Foundation 2023 guidelines): CF is confirmed if at least one of the following is true:

- Nasal potential difference measurement: Nasal potential difference (NPD) test measures the voltage difference across nasal epithelium, reflecting abnormal CFTR-mediated ion transport. In CF, NPD is abnormally negative due to increased sodium reabsorption (ENaC hyperactivity). This test is highly sensitive and specific but not widely available and requires expertise; it's reserved for cases with clinical suspicion but borderline/unavailable sweat testing or equivocal genetics. Normal NPD = -10 to -30 mV; CF typically < -40 mV.